MGO One Seven LLC Buys 11,678 Shares of Edwards Lifesciences Corporation $EW

MGO One Seven LLC lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 160.7% during the third quarter, Holdings Channel reports. The fund owned 18,944 shares of the medical research company’s stock after buying an additional 11,678 shares during the quarter. MGO One Seven LLC’s holdings in Edwards Lifesciences were worth $1,473,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Parkside Financial Bank & Trust raised its holdings in shares of Edwards Lifesciences by 9.8% during the second quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock valued at $114,000 after purchasing an additional 130 shares during the period. Prosperity Consulting Group LLC increased its position in Edwards Lifesciences by 3.2% in the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock valued at $337,000 after buying an additional 132 shares in the last quarter. NewSquare Capital LLC raised its stake in Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares during the period. Empirical Finance LLC raised its stake in Edwards Lifesciences by 0.6% during the 2nd quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company’s stock worth $1,668,000 after buying an additional 134 shares during the period. Finally, Alpine Bank Wealth Management boosted its holdings in Edwards Lifesciences by 10.7% in the third quarter. Alpine Bank Wealth Management now owns 1,392 shares of the medical research company’s stock worth $108,000 after acquiring an additional 135 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total transaction of $971,384.40. Following the sale, the vice president directly owned 31,870 shares in the company, valued at approximately $2,729,984.20. This trade represents a 26.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,700 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,370,184.06. This represents a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 57,824 shares of company stock valued at $4,863,323. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $84.34 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The firm has a 50-day moving average of $85.10 and a 200-day moving average of $80.50. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The company has a market cap of $48.94 billion, a P/E ratio of 36.35, a P/E/G ratio of 3.33 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the firm posted $0.67 EPS. The firm’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on EW shares. Wells Fargo & Company set a $100.00 price objective on Edwards Lifesciences in a report on Thursday, December 18th. The Goldman Sachs Group restated a “buy” rating and set a $108.00 price target on shares of Edwards Lifesciences in a research note on Friday, January 9th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Mizuho lifted their price objective on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Finally, Evercore ISI restated an “outperform” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Monday, January 5th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $96.45.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.